Literature DB >> 20348838

Dose optimization of somatostatin analogues for acromegaly patients.

A Colao1, G Lombardi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20348838     DOI： 10.1007/BF03346566

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  24 in total

1.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

2.  First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

Authors:  A Colao; E Martino; P Cappabianca; R Cozzi; M Scanarini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

3.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.

Authors:  I M Holdaway; M J Bolland; G D Gamble
Journal:  Eur J Endocrinol       Date:  2008-06-04       Impact factor: 6.664

4.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

5.  Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.

Authors:  J Feenstra; W W de Herder; S M T H ten Have; A W van den Beld; R A Feelders; J A M J L Janssen; A J van der Lely
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

6.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

7.  Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.

Authors:  H Biering; B Saller; J Bauditz; M Pirlich; B Rudolph; A Johne; M Buchfelder; K Mann; M Droste; I Schreiber; H Lochs; C J Strasburger
Journal:  Eur J Endocrinol       Date:  2006-02       Impact factor: 6.664

8.  Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

Authors:  I Lancranjan; A B Atkinson
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

9.  Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly.

Authors:  Annamaria Colao; Rosario Pivonello; Renata S Auriemma; Mariano Galdiero; Silvia Savastano; Gaetano Lombardi
Journal:  Eur J Endocrinol       Date:  2007-11       Impact factor: 6.664

10.  High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

Authors:  Andrea Giustina; Stefania Bonadonna; Giovanna Bugari; Annamaria Colao; Renato Cozzi; Salvatore Cannavo; Laura de Marinis; Ettore Degli Uberti; Fausto Bogazzi; Gherardo Mazziotti; Francesco Minuto; Marcella Montini; Ezio Ghigo
Journal:  Eur J Endocrinol       Date:  2009-05-22       Impact factor: 6.664
View more
  1 in total

Review 1.  Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.

Authors:  Maria Fleseriu
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.